1-[1]naphthyl-butan-1-ol | 102238-72-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 1-[1]naphthyl-butan-1-ol
• 英文别名: 1-(1-Naphthyl)-1-butanol；1-naphthalen-1-ylbutan-1-ol
• CAS: 102238-72-2
• 化学式: C₁₄H₁₆O
• 分子量: 200.28
• InChiKey: PZEHYWHITYGUJY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-[1]naphthyl-butan-1-ol 在 2-碘酰基苯甲酸 作用下， 以 乙酸乙酯 为溶剂， 生成 1-萘-1-基丁烷-1-酮
  参考文献：
  名称：

  Fc-PIP催化的芳基烯基甲醇的动力学拆分

  摘要：

  开发了有效的动力学拆分非芳基酰基转移催化剂Fc-PIP催化的各种芳基烯基羰基醇的方法，可提供相应的未反应的醇，其ee值高达99％，优良的ee值高达24。

  DOI：

  10.1002/cjoc.201200410
• 作为产物：
  描述：

  1-萘-1-基丁烷-1-酮 在 lithium aluminium tetrahydride 、 乙醚 作用下， 生成 1-[1]naphthyl-butan-1-ol
  参考文献：
  名称：

  分子内酰化。第二部分 一些β-取代的β-1-萘丙酸的闭环

  摘要：

  DOI：

  10.1039/jr9540001792

文献信息

• [EN] FUSED-RING PYRIMIDIN-4(3H)-ONE DERIVATIVES, PROCESSES FOR THE PREPARATION AND USES THEREOF<br/>[FR] DERIVES DE LA PYRIMIDIN-4(3H)-ONE A CYCLES FUSIONNES, SPN PROCEDE DE PREPARATION ET SES UTILISATIONS
  申请人：SANKYO CO

  公开号：WO2003106435A1

  公开（公告）日：2003-12-24

  AbstractNovel compounds of the following formula (I) and pharmacologically acceptable salt and esters thereof can modulate LXR function and as a result show excellent anti-arteriosclerotic and anti-inflammatory activity:wherein:A represents aryl or heteroaryl;R1, R2 and R3 are the same or different and each represents hydrogen, hydroxyl, nitro, cyano, amino, halogen, carboxy, carbamoyl, mercapto, alkyl, haloalkyl, alkylcarbonyloxy, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, dialkylamino, alkylcarbonylamino, N-(alkylcarbonyl)-N-(alkyl)amino, alkoxycarbonylamino, N-(alkoxycarbonyl)-N-(alkyl)amino, alkylsulfonylamino, N-(alkylsulfonyl)-N-(alkyl)amino, haloalkylsulfonylamino, N-(haloalkylsulfonyl)-N-(alkyl)amino, alkylcarbonyl, alkoxycarbonyl, alkylaminocarbonyl or dialkylaminocarbonyl group, or R1 and R2 together are alkylenedioxy;R4 and R5 are the same or different and each represents hydrogen, hydroxyl, amino, halogen, mercapto, alkyl, haloalkyl, alkoxy, alkoxycarbonyl or alkylthio;X represents hydrogen, hydroxyl, halogen, alkoxy or haloalkoxy; andY represents an optionally substituted alkyl, cycloalkyl, heterocyclyl, aryl, cycloalkylalkyl, heterocyclylalkyl or aralkyl group.

  新化合物具有以下式（I）的结构，其药学上可接受的盐和酯可以调节LXR功能，从而表现出优秀的抗动脉粥样硬化和抗炎活性：其中：A代表芳基或杂环芳基；R1、R2和R3相同或不同，每个代表氢、羟基、硝基、氰基、氨基、卤素、羧基、氨基甲酰基、巯基、烷基、卤代烷基、烷基羰氧基、烷氧基、烷硫基、烷磺基、烷基氨基、二烷基氨基、烷基羰基氨基、N-（烷基羰基）-N-（烷基）氨基、烷氧羰基氨基、N-（烷氧羰基）-N-（烷基）氨基、烷磺酰氨基、N-（烷磺酰基）-N-（烷基）氨基、卤代烷基磺酰氨基、N-（卤代烷基磺酰基）-N-（烷基）氨基、烷基羰基、烷氧羰基、烷基氨基羰基或二烷基氨基羰基，或R1和R2一起是亚烷二氧基；R4和R5相同或不同，每个代表氢、羟基、氨基、卤素、巯基、烷基、卤代烷基、烷氧基、烷氧羰基或烷硫基；X代表氢、羟基、卤素、烷氧基或卤代烷氧基；Y代表可选择取代的烷基、环烷基、杂环烷基、芳基、环烷基烷基、杂环烷基烷基或芳基烷基。
• Alpha-substituted carboxylic acid derivatives
  申请人：SANKYO COMPANY, LIMITED

  公开号：US20030069294A1

  公开（公告）日：2003-04-10

  The &agr;-substituted carboxylic acid derivatives having the formula (I): 1 wherein R 1 is an alkyl group, etc., R 2 is a hydrogen atom, etc., R 3 is a hydrogen atom, etc., A is ═CH-group, etc., B is an oxygen atom, etc., W 1 is a C 1 -C 8 alkylene group, W 2 is a single bond or a C 1 -C 8 alkylene group, X is a hydrogen atom, etc., Y is an oxygen atom, etc., and Z 1 is an alkoxy group, etc., and pharmacologically acceptable salts, esters and amides thereof are useful for treatment and/or prevention of diabetes mellitus, impaired glucose tolerance, gestational diabetes mellitus, or the like. Some of the derivatives of the formula (I) are novel compounds.

  具有如下式(I)的α-取代羧酸衍生物，其中R1是烷基基团，R2是氢原子，R3是氢原子，A是═CH-基团，B是氧原子，W1是C1-C8烷基基团，W2是单键或C1-C8烷基基团，X是氢原子，Y是氧原子，Z1是烷氧基团，其药理学上可接受的盐、酯和酰胺对于治疗和/或预防糖尿病、糖耐量受损、妊娠期糖尿病等疾病是有用的。其中一些具有如上式(I)的衍生物是新化合物。
• New beta-amino-alpha-hydroxycarboxylic acids and their use
  申请人：Sankyo Company Limited

  公开号：EP0498680A1

  公开（公告）日：1992-08-12

  The compounds of the invention are β-amino-α-hydroxycarboxylic acid derivatives having the formula (I): wherein: R¹ represents a group of formula R(Z)xA-    wherein R is hydrogen, or a substituted or unsubstituted alkyl, alkenyl, alkynyl, aryl or heterocyclic group or R is a group of formula -NRaRb wherein Ra and Rb are hydrogen atoms, alkyl groups, unsubstituted or substituted cycloalkyl, heterocyclic, aralkenyl or aryl groups,    Z represents oxygen or sulphur;    A represents a group of formula -CO-, -COCO-, -SO-, -SO₂- or -CS-; and    x is the cipher 0 or the integer 1; R² represents a hydrogen atom, or a substituted or unsubstituted alkyl group; R³ is hydrogen, or a substituted or unsubstituted alkyl, alkenyl, alkynyl, aryl or heterocyclic group; R⁴ is a hydrogen atom, a substituted or unsubstituted alkyl, aryl or heterocyclic group;    and R⁵ represents a group of formula -B-(CO)-Y-Rcy , wherein    B represents a heterocyclic group unsubstituted or substituted with at least one alkyl group;    Y represents an oxygen atom, a nitrogen atom or a sulphur atom;    y is the integer 1 when Y represents an oxygen atom or a sulphur atom, and 2 when Y represents a nitrogen atom; and    Rc represents       is hydrogen, or a substituted or unsubstituted alkyl, alkenyl, alkynyl, aryl or heterocyclic group;    and, where there are two groups or atoms represented by Rc, they are the same or different; and and pharmaceutically acceptable salts and esters thereof.

  本发明的化合物是β-氨基-α-羟基羧酸衍生物，具有以下式子（I）：其中：R¹表示以下式子的基团R（Z）xA-，其中R为氢，或取代或未取代的烷基，烯基，炔基，芳基或杂环基，或R为以下式子的基团-NRaRb，其中Ra和Rb为氢原子，烷基，未取代或取代的环烷基，杂环基，芳烯基或芳基；Z表示氧或硫；A表示以下式子的基团-CO-，-COCO-，-SO-，-SO₂-或-CS-；x为0或整数1；R²表示氢原子，或取代或未取代的烷基；R³为氢，或取代或未取代的烷基，烯基，炔基，芳基或杂环基；R⁴为氢原子，取代或未取代的烷基，芳基或杂环基；和R⁵表示以下式子的基团-B-（CO）-Y-Rcy，其中B表示未取代或取代的至少有一个烷基的杂环基；Y表示氧原子，氮原子或硫原子；当Y表示氧原子或硫原子时，y为整数1，当Y表示氮原子时，y为整数2；并且Rc表示氢原子，或取代或未取代的烷基，烯基，炔基，芳基或杂环基；当有两个由Rc表示的基团或原子时，它们是相同的或不同的；以及其药学上可接受的盐和酯。
• 5-DEUTERO-2,4-THIAZOLIDINEDIONE AND 5-DEUTERO-2,4-OXAZOLIDINEDIONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME
  申请人：DeuteRx, LLC

  公开号：US20140221369A1

  公开（公告）日：2014-08-07

  The invention provides 5-deuterium enriched 2,4-thiazolidinediones and 2,4-oxazolidinediones, such as 5-(4-((6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzo[d]imidazol-2-yl)methoxy)benzyl)-5-deutero-thiazolidine-2,4-dione, deuterated derivatives thereof, stereoisomers thereof, pharmaceutically acceptable salt forms thereof, and methods of treating medical disorders, such as cancer, using the same.

  该发明提供了5-氘富集的2,4-噻唑烷二酮和2,4-噁唑烷二酮，例如5-（4-（（6-（4-氨基-3,5-二甲基苯氧基）-1-甲基-1H-苯并[d]咪唑-2-基）甲氧基）苄基）-5-氘噻唑烷-2,4-二酮，其氘代衍生物，其立体异构体，其药学上可接受的盐形式，以及使用它们治疗医学疾病（例如癌症）的方法。
• Medicinal compositions containing diuretic and insulin resistance-improving agent
  申请人：Takaoka Masaya

  公开号：US20050288339A1

  公开（公告）日：2005-12-29

  The present invention relates to a pharmaceutical composition comprising an insulin sensitizer and a diuretic which can prevent or treat side effects such as edema, cardiac enlargement, body fluid retension or hydrothorax caused by administration of an insulin sensitizer.

  本发明涉及一种药物组合物，包括胰岛素增敏剂和利尿剂，可以预防或治疗由于胰岛素增敏剂的使用引起的水肿、心脏肥大、体液潴留或胸水等副作用。